A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab

Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®

NCT04313270 ·Status: RECRUITING

Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease

NCT03355027 ·Status: UNKNOWN ·Phase: NA

The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients

NCT05579418 ·Status: UNKNOWN ·Phase: PHASE4

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

NCT04790513 ·Status: COMPLETED ·Phase: PHASE3

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

NCT01604824 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

NCT01644188 ·Status: COMPLETED ·Phase: PHASE3

Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients

NCT04397653 ·Status: UNKNOWN ·Phase: PHASE4

Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography

NCT04338165 ·Status: UNKNOWN ·Phase: PHASE2

Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia

NCT04659525 ·Status: UNKNOWN ·Phase: PHASE4

Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

NCT05192941 ·Status: COMPLETED ·Phase: PHASE4

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

NCT01709513 ·Status: COMPLETED ·Phase: PHASE3

Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients

NCT02001883 ·Status: UNKNOWN ·Phase: PHASE4

Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.

NCT05888103 ·Status: COMPLETED ·Phase: PHASE3

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

NCT03397121 ·Status: COMPLETED ·Phase: PHASE3

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

NCT02476006 ·Status: COMPLETED ·Phase: PHASE3

Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

NCT05004675 ·Status: COMPLETED ·Phase: PHASE3

Clinical Trial of PCSK9 Inhibitor and Statin Treatment for Carotid Artery Stenosis

NCT07036991 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

NCT04765657 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography

NCT04851769 ·Status: COMPLETED ·Phase: PHASE4

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

NCT02867813 ·Status: COMPLETED ·Phase: PHASE3

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

NCT01644175 ·Status: COMPLETED ·Phase: PHASE3

Patterns of Inclisiran Use in the Real World: An Analysis of US Databases

NCT07023445 ·Status: COMPLETED

Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

NCT05661552 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

NCT01623115 ·Status: COMPLETED ·Phase: PHASE3